Infl iximab versus ciclosporin in severe ulcerative colitis
暂无分享,去创建一个
[1] S. Targan,et al. Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis , 2010, Gut.
[2] A. Kornbluth,et al. Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee , 2010, The American Journal of Gastroenterology.
[3] Paul Rutgeerts,et al. Infliximab for induction and maintenance therapy for ulcerative colitis. , 2005, The New England journal of medicine.
[4] Gordon H Guyatt,et al. Randomized trials stopped early for benefit: a systematic review. , 2005, JAMA.
[5] Å. Danielsson,et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. , 2005, Gastroenterology.
[6] P. Rutgeerts,et al. Long-term Outcome of Treatment with Intravenous Cyclosporin in Patients With Severe Ulcerative Colitis , 2004, Inflammatory bowel diseases.
[7] P. Rutgeerts,et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. , 2003, Gastroenterology.
[8] S. Targan,et al. Infliximab in the Treatment of Severe, Steroid-Refractory Ulcerative Colitis: A Pilot Study , 2001, Inflammatory bowel diseases.
[9] A. Kornbluth,et al. Ulcerative colitis practice guidelines in adults , 1997 .
[10] S. Hanauer,et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. , 1994, The New England journal of medicine.
[11] D. Present,et al. Preliminary report: cyclosporin in treatment of severe active ulcerative colitis , 1990, The Lancet.
[12] D. Jewell,et al. Intensive intravenous regimen for severe attacks of ulcerative colitis. , 1974, Lancet.